Prostate cancer is a common cancer in men that originates in the prostate gland and often has no obvious symptoms in the early stages. As the disease progresses, urinary symptoms such as frequent urination, urgent need to urinate, and difficulty or pain during urination may occur, along with decreased sexual function, such as erectile dysfunction, as well as other symptoms like bone pain and weigh
Conditions
Interventions
Index test:Equipment: PET/CT
Tracer: PSMA
Sponsors
The First Affiliated Hospital of Nanchang University
Eligibility
Sex/Gender
Male
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1.Age >=18 years old and =0.2ng/mL; 4. After radical radiotherapy (as defined by the ASTRO-Phoenix consensus) : PSA increases by >=2ng/mL from the minimum value. 5.Karnofsky physical condition >=60 (or ECOG/WHO equivalent score). 6. Blood routine: WBC>=4×10^9/L, Platelet>=100×10^9/L, Hb>=90g/L. 7. Liver function: ALT, AST, ALP, TBil=28g/L. 8. Renal function: Creatinine clearance rate >=30ml/min. 9. The expected survival time exceeds 12 months. 10. Agree to strict contraception for at least 28 days after administration of 18F-PSMA-11. 11. Be willing and able to abide by planned visits, diagnostic plans, clinical laboratory tests and other trial procedures.
Exclusion criteria
Exclusion criteria: 1.History of any other malignancies in the past year, except for non-metastatic basal cell carcinoma of the skin, superficial squamous cell carcinoma of the skin, and superficial bladder cancer. 2.Previous use of radioactive isotopes with a time interval of less than 10 physical half-lives from the time of study drug administration. 3.Currently participating or planning to participate in any clinical trials involving drugs or devices during the study period. 4.Known allergy to the active ingredient or components of 18F-PSMA-11. 5.Inability to lie flat or remain still during a PET scan, or intolerance to PET scanning. 6.Presence of abnormalities in physical examination, ECG, or clinical laboratory tests during the screening period that, in the investigator's judgment, may affect safety or adherence. 7.Those who, in the opinion of the investigator, should not participate in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Diagnostic sensitivity;Specificity; | — |
Countries
China
Contacts
Public ContactQing Zhang;Qing Zhang
The First Affiliated Hospital of Nanchang University
Outcome results
None listed